RESUMEN
High-risk Human papilloma virus (HPV) types are the causative agents of cervical cancer and several other anogenital malignancies. The viral proteins expressed in the (pre)malignant cells are considered ideal targets for immunological intervention. Many approaches have been evaluated for this purpose, mostly aiming at the induction of HPV16 E7- and/or E6-specific cellular immunogenicity. As clinical success has so far been limited, novel approaches are required. We describe the development and pre-clinical testing of a vaccine candidate consisting of replication-deficient adenovirus type 26 and 35 based vectors for the interception of HPV16- and HPV18-related disease. We developed HPV16- and HPV18-specific antigens consisting of fusion proteins of E2, E6 and E7. The vaccine will be suitable for every disease stage, from incident and persistent infections where E2 is predominantly expressed up to late stages where E6 and E7 expression are upregulated. Importantly E6 and E7 are present as reordered fragments to abrogate the transforming activity of these two proteins. Loss of transforming activity was demonstrated in different in vitro models. Robust T-cell immunogenicity was induced upon immunization of mice with the vaccine candidate. Finally, the developed vaccine vectors showed considerable therapeutic efficacy in the TC-1 mouse model. The absence of transforming activity of the antigens and the favorable immunogenicity profile of the adenovirus based vectors along with the fact that these vectors can be readily produced on a large scale makes this approach attractive for clinical evaluation.
Asunto(s)
Dependovirus/fisiología , Papillomavirus Humano 16/inmunología , Papillomavirus Humano 18/inmunología , Infecciones por Papillomavirus/terapia , Neoplasias del Cuello Uterino/terapia , Animales , Antígenos Virales de Tumores/inmunología , Femenino , Humanos , Ratones , Células 3T3 NIH , Vacunas contra Papillomavirus/inmunología , Neoplasias del Cuello Uterino/virología , Replicación Viral , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
During the development of human adenovirus 35-derived replication-incompetent (rAd35) vaccine vectors for prevention of infectious diseases, we detected mutations in the terminal 8 nt of the inverted terminal repeats (ITRs) of rAd35. The switch from the plasmid-encoded sequence 5'-CATCATCA-3' to the alternative sequence 5'-CTATCTAT-3' in the ITRs was found to be a general in vitro propagation phenomenon, as shown for several vectors carrying different transgenes or being derived from different adenovirus serotypes. In each tested case, the plasmid-encoded ITR sequence changed to exactly the same alternative ITR sequence, 5'-CTATCTAT-3'. The outgrowth of this alternative ITR version should result from a growth advantage conferred by the alternative ITR sequence. Indeed, replication kinetics studies of rAd35 harbouring either the original or alternative ITR sequence confirmed an increase in replication speed for rAd35 vectors with the alternative ITR sequence. These findings can be applied to generate recombinant adenoviral vectors harbouring the alternative ITR sequence, which will facilitate the generation of genetically homogeneous seed virus batches. Moreover, vector production may be accelerated by taking advantage of the observed improved replication kinetics associated with the alternative ITR sequence.
Asunto(s)
Adenoviridae/fisiología , Secuencias Repetidas Terminales , Replicación Viral , Adenoviridae/genética , Animales , Línea Celular , Replicación del ADN , Vectores Genéticos , Humanos , Mutación , PlásmidosRESUMEN
BACKGROUND: The JAK/STAT (Janus Tyrosine Kinase, Signal Transducers and Activators of Transcription) pathway is associated with cytokine or growth factor receptors and it is critical for growth control, developmental regulation and homeostasis. The use of porcine ocular cells as putative xenotransplants appears theoretically possible. The aim of this study was to investigate the response of various porcine ocular cells in vitro to human cytokines in regard to the activation of JAK-STAT signaling pathways. METHODS: Porcine lens epithelial cells, pigmented iris epithelial cells and pigmented ciliary body cells were used in this study. These cells were isolated from freshly enucleated porcine eyes by enzymatic digestion. Cultured cells between passages 3-8 were used in all experiments. Electromobility shift assay (EMSA), proliferation assay, immunofluorescence staining and flow cytometry were used to evaluate the JAK-STAT signaling pathway in these cells. RESULTS: JAK/STAT signaling pathways could be activated in porcine pigmented epithelial ciliary body cells, in pigmented iris epithelial cells and in lens epithelial cells in response to porcine and human interferons and cytokines. All cells showed very strong STAT1 activation upon stimulation with porcine interferon-gamma. Porcine ocular cells also respond to human cytokines; IFN-alpha induced strong activation of STAT1 in EMSA, flow cytometry and immunofluorescence experiments whereas activation of STAT3 was less strong in EMSA, but strong in flow cytometry and immunofluorescence. Human recombinant IL-6 activated STAT3 and human IL-4 activated STAT6. With the help of immunofluorescence assay and flow cytometry we observed nuclear localization of STAT proteins after activation of porcine ocular cells with cytokines and interferons. Human IFN-α had an inhibitory effect on porcine ocular cells in proliferation assays. CONCLUSION: Our study demonstrated that some types of human cytokines and interferon activate intracellular JAK-STAT signaling pathways in porcine ocular cells. We hypothesize that direct stimulation of the JAK-STAT pathway in porcine cells in response to human cytokines will lead to complications or failure, if pig-to-human ocular tissue xenotransplantation were to be carried out. For successful xenotransplantation among other obstacles there must be new approaches developed to regulate signaling pathways.
Asunto(s)
Citocinas/metabolismo , Ojo/inmunología , Ojo/metabolismo , Quinasas Janus/metabolismo , Factores de Transcripción STAT/metabolismo , Sus scrofa/inmunología , Sus scrofa/metabolismo , Animales , Proliferación Celular , Cuerpo Ciliar/citología , Cuerpo Ciliar/inmunología , Cuerpo Ciliar/metabolismo , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Ojo/citología , Femenino , Xenoinjertos , Humanos , Interferones/metabolismo , Iris/citología , Iris/inmunología , Iris/metabolismo , Cristalino/citología , Cristalino/inmunología , Cristalino/metabolismo , Masculino , Transducción de Señal , Especificidad de la EspecieRESUMEN
To develop a novel attenuation strategy applicable to all influenza A viruses, we targeted the highly conserved protein-protein interaction of the viral polymerase subunits PA and PB1. We postulated that impaired binding between PA and PB1 would negatively affect trimeric polymerase complex formation, leading to reduced viral replication efficiency in vivo. As proof of concept, we introduced single or multiple amino acid substitutions into the protein-protein-binding domains of either PB1 or PA, or both, to decrease binding affinity and polymerase activity substantially. As expected, upon generation of recombinant influenza A viruses (SC35M strain) containing these mutations, many pseudo-revertants appeared that partially restored PA-PB1 binding and polymerase activity. These polymerase assembly mutants displayed drastic attenuation in cell culture and mice. The attenuation of the polymerase assembly mutants was maintained in IFNα/ß receptor knock-out mice. As exemplified using a H5N1 polymerase assembly mutant, this attenuation strategy can be also applied to other highly pathogenic influenza A virus strains. Thus, we provide proof of principle that targeted mutation of the highly conserved interaction domains of PA and PB1 represents a novel strategy to attenuate influenza A viruses.
Asunto(s)
Subtipo H5N1 del Virus de la Influenza A/enzimología , Subtipo H7N7 del Virus de la Influenza A/enzimología , Gripe Humana/enzimología , Mutación , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Virales/metabolismo , Animales , Perros , Humanos , Subtipo H5N1 del Virus de la Influenza A/genética , Subtipo H5N1 del Virus de la Influenza A/inmunología , Subtipo H7N7 del Virus de la Influenza A/genética , Subtipo H7N7 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/biosíntesis , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/inmunología , Gripe Humana/genética , Gripe Humana/inmunología , Interferón-alfa/genética , Interferón-alfa/inmunología , Interferón-alfa/metabolismo , Interferón beta/genética , Interferón beta/inmunología , Interferón beta/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , ARN Polimerasa Dependiente del ARN/genética , ARN Polimerasa Dependiente del ARN/inmunología , Vacunas Atenuadas/biosíntesis , Vacunas Atenuadas/genética , Vacunas Atenuadas/inmunología , Proteínas Virales/genética , Proteínas Virales/inmunología , Replicación Viral/genética , Replicación Viral/inmunologíaRESUMEN
Assembly of the heterotrimeric influenza virus polymerase complex from the individual subunits PB1, PA, and PB2 is a prerequisite for viral replication. The conserved protein-protein interaction sites have been suggested as potential drug targets. To characterize the PB1-PB2 interface, we fused the PB1-binding domain of PB2 to green fluorescent protein (PB2(1-37)-GFP) and determined its competitive inhibitory effect on the polymerase activity of influenza A virus strains. Coexpression of PB2(1-37)-GFP in a polymerase reconstitution system led to substantial inhibition of the polymerase of A/WSN/33 (H1N1). Surprisingly, polymerases of other strains, including A/SC35M (H7N7), A/Puerto Rico/8/34 (H1N1), A/Hamburg/4/2009 (H1N1), and A/Thailand/1(KAN-1)/2004 (H5N1), showed various degrees of resistance. Individual exchange of polymerase subunits and the nucleoprotein between the sensitive WSN polymerase and the insensitive SC35M polymerase mapped the resistance to both PB1 and PA of SC35M polymerase. While PB2(1-37)-GFP bound equally well to the PB1 subunits of both virus strains, PB1-PA dimers of SC35M polymerase showed impaired binding compared to PB1-PA dimers of WSN polymerase. The use of PA(SC35M/WSN) chimeras revealed that the reduced affinity of the SC35M PB1-PA dimer was mediated by the N-terminal 277 amino acids of PA. Based on these observations, we speculate that the PB1-PA dimer formation of resistant polymerases shields the PB2(1-37) binding site, whereas sensitive polymerases allow this interaction, suggesting different assembly strategies of the trimeric polymerase complex between different influenza A virus strains.
Asunto(s)
Virus de la Influenza A/fisiología , Multimerización de Proteína , Proteínas Virales/metabolismo , Replicación Viral , Fusión Artificial Génica , Sitios de Unión , Línea Celular , Genes Reporteros , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Unión Proteica , Mapeo de Interacción de Proteínas , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Coloración y EtiquetadoRESUMEN
Due to their ability to rapidly mutate, influenza viruses quickly develop resistance against many antiviral substances, leading to an urgent need for new compounds. The trimeric viral polymerase complex, a major target for the development of new inhibitors, must be assembled from the PB1, PB2, and PA subunits for successful infection. Here, we describe ELISA-based assays which allow the identification of peptides which impair polymerase complex formation. Since the protein-protein interaction domains of the viral polymerase are highly conserved, these inhibitors are also predicted to be active against a broad range of influenza strains. Using this method, identification of small molecules and lead compounds against influenza A and B viruses should be feasible.
Asunto(s)
Antivirales/síntesis química , Evaluación Preclínica de Medicamentos/métodos , Gripe Humana/tratamiento farmacológico , Orthomyxoviridae/efectos de los fármacos , ARN Polimerasa Dependiente del ARN/antagonistas & inhibidores , Proteínas Virales/antagonistas & inhibidores , Antivirales/química , Unión Competitiva , Células HEK293 , Humanos , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/química , Unión Proteica , Multimerización de Proteína/efectos de los fármacos , ARN Polimerasa Dependiente del ARN/química , Proteínas Virales/químicaRESUMEN
Despite their close phylogenetic relationship, natural intertypic reassortants between influenza A (FluA) and B (FluB) viruses have not been described. Inefficient polymerase assembly of the three polymerase subunits may contribute to this incompatibility, especially because the known protein-protein interaction domains, including the PA-binding domain of PB1, are highly conserved for each virus type. Here we show that substitution of the FluA PA-binding domain (PB1-A(1-25)) with that of FluB (PB1-B(1-25)) is accompanied by reduced polymerase activity and viral growth of FluA. Consistent with these findings, surface plasmon resonance spectroscopy measurements revealed that PA of FluA exhibits impaired affinity to biotinylated PB1-B(1-25) peptides. PA of FluB showed no detectable affinity to biotinylated PB1-A(1-25) peptides. Consequently, FluB PB1 harboring the PA-binding domain of FluA (PB1-AB) failed to assemble with PA and PB2 into an active polymerase complex. To regain functionality, we used a single amino acid substitution (T6Y) known to confer binding to PA of both virus types, which restored polymerase complex formation but surprisingly not polymerase activity for FluB. Taken together, our results demonstrate that the conserved virus type-specific PA-binding domains differ in their affinity to PA and thus might contribute to intertypic exclusion of reassortants between FluA and FluB viruses.
Asunto(s)
Virus de la Influenza A/metabolismo , Virus de la Influenza B/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular , Perros , Humanos , Cinética , Datos de Secuencia Molecular , Nucleótidos/química , Péptidos/química , Estructura Terciaria de Proteína , Proteínas Recombinantes/química , Homología de Secuencia de Aminoácido , Especificidad de la Especie , Resonancia por Plasmón de SuperficieRESUMEN
The influenza A virus polymerase complex, consisting of the subunits PB1, PB2, and PA, represents a promising target for the development of new antiviral drugs. We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1. To increase the binding affinity of these peptides, we performed a systematic structure-affinity relationship analysis. Alanine and aspartic acid scans revealed that almost all amino acids in the core binding region (aa 5 to 11) are indispensable for PA binding. Using a library of immobilized peptides representing all possible single amino acid substitutions, we were able to identify amino acid positions outside the core PA-binding region (aa 1, 3, 12, 14, and 15) that are variable and can be replaced by affinity-enhancing residues. Surface plasmon resonance binding studies revealed that combination of several affinity-enhancing mutations led to an additive effect. Thus, the feasibility to enhance the PA-binding affinity presents an intriguing possibility to increase antiviral activity of the PB1-derived peptide and one step forward in the development of an antiviral drug against influenza A viruses.
Asunto(s)
Virus de la Influenza A/enzimología , Péptidos/química , Péptidos/metabolismo , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Virales/química , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Línea Celular , Humanos , Virus de la Influenza A/metabolismo , Datos de Secuencia Molecular , Péptidos/síntesis química , Unión Proteica , Dominios y Motivos de Interacción de Proteínas , Relación Estructura-Actividad , Proteínas Virales/genéticaRESUMEN
PURPOSE: There is growing evidence that vasospatic individuals could be predisposed to develop glaucoma. Vasospastic deregulation is ensuing in activation of circulating leukocytes. In previous studies using "gene-hunting" strategies, we demonstrated stable alterations in gene expression profiles of circulating leukocytes isolated from glaucoma patients with vascular deregulation when compared to healthy individuals with no history of glaucomatous damage. The goal of this study was to look for possible similarities in gene expression profiles of circulating leukocytes in vasospastic individuals and glaucoma patients. METHODS: Normal-tension (NTG) and high-tension (HTG) glaucoma patients as well as individuals with vascular deregulation (VD) and healthy controls were recruited for the gene expression analysis. The methodology of comparative Expression Array analysis followed by highly sensitive quantitative real-time PCR has been used. RESULTS: Compared to the control group the expression of 146, 68, and 60 genes was found to be altered in NTG, HTG, and VD groups respectively. Thirty-four genes demonstrated similar expressional alterations in NTG, HTG, and VD groups versus controls, and only 21 genes demonstrated similar expressional alterations in NTG and HTG groups, having no overlap with the VD group. CONCLUSIONS: This result indicates a potential predisposition of vasospastic individuals to glaucomatous optic nerve atrophy. The targeted expression profiles might be further considered for early/predictive glaucoma diagnosis.
Asunto(s)
Perfilación de la Expresión Génica , Glaucoma/genética , Leucocitos/metabolismo , Enfermedades Vasculares/genética , Estudios de Casos y Controles , Regulación de la Expresión Génica , Humanos , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The retinal pigment epithelial cell line ARPE-19 was established in 1996 and remains widely used today for biomedical and in particular ophthalmology research. We have analyzed the chromosomes of the ARPE-19 cell line and found cultured cells exist as a heterogeneous mixture having both normal karyotypes and chromosomal rearrangements. In ARPE-19 cells, we observed metaphases with a single translocation t(15;19) and metaphases with two translocations t(5;15) and t(15;19) and a derivative chromosome 9. Aneuploidies have also been detected (monosomy: -16; trisomy: +11, +18). Multiple attempts to isolate clones with a normal karyotype from those with aberrant karyotypes failed due to senescence of cells of normal karyotypes. We could, however, isolate clones with the translocation t(15;19) and clones with two translocations t(5;15) and t(15;19). In continued cell culture after second subcloning for 30 passages, all clones maintained their cytogenetic integrity.We have further investigated the chromosomal profiles of the ARPE-19 cell line from another laboratory and observed cells with a normal karyotype as well as abnormalities in chromosomes 6p and 11q. The DNA profiles of the ARPE-19 cells from both labs were identical to the ATCC profiles, excluding contamination with other cell lines. Since chromosomal translocations in ARPE-19 cells differ from lab to lab and display a mosaicism for structural chromosomal aberrations, researchers dealing with ARPE-19 cells should screen their stocks for chromosomal aberrations and proceed with caution against misinterpretations during experimental manipulations with this cell line. This chapter describes in detail our laboratory methods for single cell cloning, karyotype analysis and fluorescence in situ hybridization (FISH), which we used for the identification and characterization of chromosomal translocations in the retinal pigment epithelial cell line ARPE-19.
Asunto(s)
Aberraciones Cromosómicas , Células Epiteliales/metabolismo , Mosaicismo , Epitelio Pigmentado de la Retina/citología , Línea Celular , Humanos , Hibridación Fluorescente in Situ , Cariotipo , Análisis de la Célula Individual , Translocación GenéticaRESUMEN
Genetic vaccines based on replication-incompetent adenoviral (AdV) vectors are currently in clinical development. Monovalent AdV vectors express one antigen from an expression cassette placed in most cases in the E1 region. For many vaccines, inclusion of several antigens is necessary in order to raise protective immunity and/or target more than one pathogen or pathogen strain. On the basis of the current technology, a mix of several monovalent vectors can be employed. However, a mix of the standard monovalent AdV vectors may not be optimal with respect to manufacturing costs and the final dose per vector in humans. Alternatively, a variety of bivalent recombinant AdV vector approaches is described in the literature. It remains unclear whether all strategies are equally suitable for clinical development while preserving all the beneficial properties of the monovalent AdV (e.g., immunogenic potency). Therefore, a thorough assessment of different bivalent AdV strategies was performed in a head-to-head fashion compared with the monovalent benchmark. The vectors were tested for rescue efficiency, genetic stability, transgene expression, and potency to induce transgene-specific immune responses. We report that the vector expressing multiple antigens from a bidirectional expression cassette in E1 shows a better genetic stability profile and a potent transgene-specific immune response compared with the other tested bivalent vectors.
Asunto(s)
Adenoviridae , Expresión Génica , Vectores Genéticos , Transgenes/inmunología , Células A549 , Adenoviridae/genética , Adenoviridae/inmunología , Animales , Vectores Genéticos/genética , Vectores Genéticos/inmunología , Humanos , Ratones , Ratones Endogámicos BALB CRESUMEN
Oncogenic high-risk human papillomavirus (HPV) infections cause a substantial number of genital and non-genital cancers worldwide. Approximately 70% of all cervical cancers are caused by the high-risk HPV16 and 18 types. The remaining 30% can be attributed to twelve other high-risk HPV-types. Highly efficacious 2-valent, 4-valent and 9-valent L1 protein based prophylactic HPV vaccines are available however with limited cross-protection. To further increase the coverage, development of a multivalent cross-protective HPV vaccine is currently focused on the conserved N-terminus of HPV's L2 protein. We have developed a vaccine candidate based on the rare human adenovirus type 35 (HAdV35) vector that displays a concatemer of L2 protein epitopes from four different HPV-types via protein IX (pIX). A mix of two heterologous HAdV35 pIX-L2 display vectors present highly conserved linear epitopes of nine HPV-types. Each HAdV35 pIX-L2 display vector exhibits a good manufacturability profile. HAdV35 pIX-L2 display vaccine vectors were immunogenic and induced neutralizing antibodies against HPV-types included in the vaccine and cross-neutralizing antibodies against distant a HPV-type not included in the vaccine in mice. The HAdV35 pIX-L2 display vectors offer an opportunity for a multivalent HAdV-based prophylactic HPV vaccine.
Asunto(s)
Adenoviridae/genética , Inmunidad Humoral/inmunología , Papillomaviridae/inmunología , Vacunas contra Papillomavirus/inmunología , Animales , Anticuerpos Neutralizantes/inmunología , Proteínas de la Cápside/inmunología , Reacciones Cruzadas/inmunología , Femenino , Cinética , Espectrometría de Masas , RatonesRESUMEN
[This corrects the article DOI: 10.1371/journal.pone.0192312.].
RESUMEN
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.
Asunto(s)
Ebolavirus/inmunología , Fiebre Hemorrágica Ebola/prevención & control , Enfermedad del Virus de Marburg/prevención & control , Marburgvirus/inmunología , Vacunas Virales/inmunología , Animales , Femenino , Macaca fascicularis , MasculinoRESUMEN
PURPOSE: Several reports have shown that proteasome levels may change during pathological processes. Here we investigated whether altered gene expression of the alpha-subunit of 20S proteasomes in leukocytes of glaucoma patients at the level of mRNA, shown by us earlier, is reflected by the level of protein synthesis. METHODS: Western blot analysis was performed to determine the protein levels of the 20S proteasome alpha-subunit in leukocytes of 12 glaucoma patients (6 HTG and 6 NTG) and 6 healthy controls. RESULTS: Plasma levels of the 20S proteasome alpha-subunit showed a 3.4+/-0.47 (mean+/-SD; p<0.0001) fold increase in glaucoma patients when compared to healthy controls. In addition, normal tension glaucoma patients revealed a more pronounced alpha-subunit expression (p<0.05) when compared to patients with high tension glaucoma. CONCLUSIONS: During the pathological process of glaucoma, proteasome protein levels increase. This indicates that proteasome protein levels may be a diagnostic or eventually a prognostic marker for glaucomatous damage.
Asunto(s)
Cisteína Endopeptidasas/sangre , Proteínas del Ojo/sangre , Glaucoma de Ángulo Abierto/enzimología , Complejos Multienzimáticos/sangre , Anciano , Biomarcadores/sangre , Western Blotting , Cisteína Endopeptidasas/genética , Proteínas del Ojo/genética , Femenino , Glaucoma de Ángulo Abierto/patología , Humanos , Presión Intraocular , Leucocitos Mononucleares/enzimología , Masculino , Persona de Mediana Edad , Complejos Multienzimáticos/genética , Complejo de la Endopetidasa Proteasomal , ARN Mensajero/metabolismo , Regulación hacia ArribaRESUMEN
PURPOSE: To quantify the gene expression levels of the ABC-proteins MDR1 (P-glycoprotein) and MRP (multidrug resistance-associated protein) isoforms in isolated mononuclear cells of vasospastic persons with increased Endothelin-1 plasma levels. METHODS: Quantitative real-time RT-PCR was performed to determine the expression levels of the MDR1 (P-glycoprotein) gene and MRP1 to MRP5 genes as well as the expression of the ETA and ETB receptor in mononuclear cells derived from 11 vasospastic subjects compared to 10 healthy controls. RESULTS: Mononuclear cells of vasospastic subjects showed a significant decrease in the expression of MDR1 (P-glycoprotein) gene (p=0.029), MRP2 gene (p=0.003), and MRP5 gene (p=0.013) when compared to healthy controls. These effects were poorly correlated with ET-1 plasma levels. No significant ETA and ETB receptor expression was observed in both groups. CONCLUSIONS: Vasospastic persons differ in their expression pattern of MDR proteins from healthy controls. This might be an indirect effect of elevated ET-1 levels.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Vasoespasmo Coronario/genética , Regulación de la Expresión Génica , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Vasoconstricción/genética , Endotelina-1/sangre , Femenino , Humanos , Masculino , Isoformas de Proteínas , ARN Mensajero/metabolismo , Receptor de Endotelina A/genética , Receptor de Endotelina B/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
There is an urgent need for new drugs against influenza type A and B viruses due to incomplete protection by vaccines and the emergence of resistance to current antivirals. The influenza virus polymerase complex, consisting of the PB1, PB2 and PA subunits, represents a promising target for the development of new drugs. We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between the PB1 and PA subunits of the polymerase complex of influenza A virus using a small peptide derived from the PA-binding domain of PB1. However, this influenza A virus-derived peptide did not affect influenza B virus polymerase activity. Here we report that the PA-binding domain of the polymerase subunit PB1 of influenza A and B viruses is highly conserved and that mutual amino acid exchange shows that they cannot be functionally exchanged with each other. Based on phylogenetic analysis and a novel biochemical ELISA-based screening approach, we were able to identify an influenza A-derived peptide with a single influenza B-specific amino acid substitution which efficiently binds to PA of both virus types. This dual-binding peptide blocked the viral polymerase activity and growth of both virus types. Our findings provide proof of principle that protein-protein interaction inhibitors can be generated against influenza A and B viruses. Furthermore, this dual-binding peptide, combined with our novel screening method, is a promising platform to identify new antiviral lead compounds.
Asunto(s)
ARN Polimerasas Dirigidas por ADN/química , Virus de la Influenza A/metabolismo , Virus de la Influenza B/metabolismo , Replicación Viral , Secuencia de Aminoácidos , Animales , Antivirales/química , Antivirales/farmacología , Línea Celular , Química Farmacéutica/métodos , Perros , Diseño de Fármacos , Humanos , Datos de Secuencia Molecular , Unión Proteica , Estructura Terciaria de Proteína , ARN Polimerasa Dependiente del ARN/química , Proteínas Recombinantes de Fusión/química , Homología de Secuencia de AminoácidoRESUMEN
Glaucomatous damage is a neurodegenerative eye disease and one of the leading causes of blindness with 67 million patients worldwide. Major currently challenging questions include early diagnosis, risk evaluation, and follow-up. Circulating leukocytes have been demonstrated as potentially important source of disease specific markers. The relevance of expression alterations in leukocytes for glaucomatous damage needs to be clarified. Noteworthy, gene expression patterns of trabecular meshwork and Schlemm's canal, which are anatomically and functionally highly relevant for glaucoma pathology, were shown to be similar to those of circulating leukocytes. Here, we report extensive alterations in characteristic protein expression patterns of circulating leukocytes for Normal-Tension and Primary Open-Angle Glaucoma, as revealed by analysis of 2-D PAGE images. Among most conservative alterations we found the protein spot identified by MALDI-TOF as basic transcription factor activating protein-2beta (AP-2ß). Western-blot analysis demonstrated significantly increased protein expression rates of AP-2ß in both Normal-Tension and Primary Open-Angle Glaucoma versus controls. AP proteins are essential factors of the basic transcription regulation; AP-2 proteins play a decisive role, particularly, in morphogenesis of eye. Conservative AP-2 up-regulation is of special importance in terms of basic transcriptional dysregulation that might be specific for glaucoma disease.
RESUMEN
PURPOSE: The Jak/STAT (Janus tyrosine kinase/signal transducers and activators of transcription) pathway is critical for growth control, developmental regulation and homeostasis. Here we studied the expression of STAT proteins in the proliferative disease of age-related macular degeneration (AMD) with choroidal neovascular membranes (CNVM). The STAT family are of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors. Abnormal activity of certain STAT family members, particularly STAT 3 and STAT 5, is associated with a wide variety of human malignancies and other diseases. Here were studied STAT activation in CNVM of patients with AMD. METHODS: Sections of formalin-fixed, paraffin-embedded samples from 8 eyes with AMD and 5 controls were included in this study. Immunohistochemical staining was performed using antibodies against activated STAT 1, STAT 3 and STAT 5 proteins, and tenascin. RESULTS: In CNVM, we observed a strong positive staining for tenascin and STAT 3 in retinal pigmented epithelial (RPE) cells restricted to areas of developing scars. In contrast, STAT 3 immunoreactivity failed in areas completely composed of fibrovascular disciform scar material. In addition, no immunoreactivity for both STAT 1 and STAT 5 was detected in all CNVM and in all control samples. CONCLUSION: In CNVM, activation of STAT 3 appears in RPE cells simultaneously with the formation of scars.
Asunto(s)
Neovascularización Coroidal/metabolismo , Proteínas de Unión al ADN/metabolismo , Degeneración Macular/metabolismo , Transactivadores/metabolismo , Anciano , Anciano de 80 o más Años , Membrana Celular/metabolismo , Neovascularización Coroidal/etiología , Femenino , Humanos , Técnicas para Inmunoenzimas , Degeneración Macular/complicaciones , Masculino , Factor de Transcripción STAT3 , Tenascina/metabolismoRESUMEN
PURPOSE: To investigate the correlation between connective tissue growth factor (CTGF) mRNA expression and immunohistochemical characteristics (expression of type I collagen and tenascin) of fibrovascular membranes of proliferative retinal diseases under in vivo conditions. METHODS: CTGF mRNA expression was investigated using in situ hybridization. Expression of type I collagen and tenascin was detected by immunohistochemical staining. RESULTS: CTGF mRNA is produced in transformed retinal pigment epithelial cells and appears also in fibroblast-like cells, which are embedded in epiretinal and subretinal membranes of proliferative retinal diseases as well as in surgically removed subretinal membranes. In all examined membranes, expression of human CTGF mRNA appears in concurrence with the expression of type I collagen and tenascin. CONCLUSIONS: The predominant expression of CTGF mRNA in the development of fibrovascular membranes of proliferative retinal diseases suggests a significant role of CTGF in the pathological course of these ocular disorders.